Skip to content

Vital USA SpO2 Accuracy Comparison to Arterial Blood CO-Oximetry

Results of the SpO2 and Pulse Rate Accuracy Comparison of VitalDetect™ to Arterial Blood CO-Oximetry and Reference ECG

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04285411
Enrollment
10
Registered
2020-02-26
Start date
2019-11-04
Completion date
2019-11-20
Last updated
2020-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Disease

Brief summary

Clinical Investigation Plan: Vital USA SpO2 Accuracy Comparison to Arterial Blood CO-Oximetry Study ID# PR 2019-353, Version: Rev 1, Date: 15 Oct 2019 Study Dates: November 4-5, 2019

Detailed description

An SpO2 accuracy comparison was conducted as part of the final validation of the VitalDetect™ pulse oximetry system. The study was conducted in accordance to Code of Federal Regulations (CFR) for Non-Significant Risk (NSR) investigational studies, following International Standards Organization (ISO) 14155:2011 as appropriate and the pulse oximetry guidelines of ISO 80601-2-61:2017 applicable sections, and Pulse Oximeters - Premarket Notifications Submissions \[510(k)s\] Guidance For Industry and Food and Drug Administration Staff (issued: March 4, 2013). The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less. A secondary goal was to evaluate the pulse rate performance simultaneously collected over the SpO2 range covered. The Pulse Rate Accuracy Root Mean Square (Arms) performance of the VitalDetect™ pulse oximetry system, were expected to meet a specification of 3 bpm.

Interventions

DEVICEAccuracy of the VitalDetect™ pulse oximetry system

The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.

Sponsors

Clinimark, LLC
CollaboratorOTHER
Vital USA, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Intervention model description

Testing was conducted under normal office environment conditions. The VitalDetect™ pulse oximetry was placed on the right index finger of all subjects to evaluate the SpO2 and pulse rate accuracy performance during steady state non-motion conditions. A Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws and the real time oxygen saturation status. The subject was in a reclined position and connected to a breathing circuit, for administering medical grade oxygen and nitrogen. The gas flow delivery was adjusted for subject comfort. Arterial blood samples were drawn during simultaneous data collection from the control pulse oximeter and the test oximeters. The blood was immediately analyzed by Reference CO-Oximetry providing functional SpO2 for the basis of the SpO2 accuracy comparison. The pulse rate for the VitalDetect™ was compared to Reference ECG Heart Rate collected during the study.

Eligibility

Sex/Gender
ALL
Age
18 Years to 52 Years
Healthy volunteers
Yes

Inclusion criteria

1. 10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance made up of either 2. Subject must have the ability to understand and provide written informed consent 3. Subject is 18 to 50 years of age 4. Subject must be willing and able to comply with study procedures and duration 5. Subject is a non-smoker or who has not smoked within 2 days prior to the study

Exclusion criteria

1. Subject is considered as being morbidly obese (defined as BMI \>39.5). 2. Compromised circulation, injury, or physical malformation of fingers, wrist, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.) 3. Female subjects that are actively trying to get pregnant or are pregnant (confirmed by positive urine pregnancy test unless the subject is known to be not of child-bearing potential). 4. Smoker Subjects who have refrained will be screened for COPD levels \>3% as assessed with a Radical 7 (Rainbow) 5. Subjects with known respiratory conditions such as: (self-reported): 1. uncontrolled / severe asthma, 2. flu, 3. pneumonia / bronchitis, 4. shortness of breath / respiratory distress, 5. unresolved respiratory or lung surgery with continued indications of health issues, 6. emphysema, COPD, lung disease. 6. Subjects with known heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review) 1. hypertension: systolic \>140mmHg, Diastolic \>90mmHg on 3 consecutive readings (reviewed during health screen). 2. have had cardiovascular surgery 3. Chest pain (angina) 4. heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen) 5. previous heart attack 6. blocked artery 7. unexplained shortness of breath 8. congestive heart failure (CHF) 9. history of stroke 10. transient ischemic attack 11. carotid artery disease 12. myocardial ischemia 13. myocardial infarction 14. cardiomyopathy 7. Self-reported health conditions as identified in the Health Assessment Form (self-reported) 1. diabetes, 2. uncontrolled thyroid disease, 3. kidney disease / chronic renal impairment, 4. history of seizures (except childhood febrile seizures), 5. epilepsy, 6. history of unexplained syncope, 7. recent history of frequent migraine headaches, 8. recent symptomatic head injury (within the last 2 months) 9. cancer / chemotherapy 8. Subjects with known clotting disorders (self-reported)

Design outcomes

Primary

MeasureTime frameDescription
Evaluate SpO2 Accuracy Per Standards for Pulse Oximetry.90 SecondsThis study was a comparative, single-center, non-randomized study conducted to evaluate the SpO2 accuracy per standards and guidelines identified above for SpO2 accuracy for pulse oximetry equipment over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison. As a secondary goal, the pulse rate accuracy was compared to ECG Heart Rate realized over the range throughout the hypoxia procedure. Testing was conducted under normal office environment conditions.

Secondary

MeasureTime frameDescription
The Pulse Rate Accuracy Compared to ECG Heart Rate.90 SecondsThe pulse rate accuracy was compared to ECG Heart Rate as recorded by the S5 Multi-parameter monitor. Passing criteria was an ARMS of 3 bpm or better based measurements observed during the pulse oximetry evaluation.

Countries

United States

Participant flow

Recruitment details

Following Institutional Review Board (IRB) approval Title: Vital USA SpO2 Accuracy Comparison to Arterial Blood CO-Oximetry, Clinimark Study ID# PR 2019-353, eleven healthy adult volunteer subjects were screened and enrolled into the study. One subject was withdrawn due to poor device placement and time sync with the control oximeter.

Participants by arm

ArmCount
ARMS SpO2 70-100%
Comparison to Reference CO-Oximetry Accuracy of the VitalDetect™ pulse oximetry system: The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
10
Total10

Baseline characteristics

CharacteristicARMS SpO2 70-100%
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
10 Participants
Age, Continuous25.9 years
STANDARD_DEVIATION 5.8
Body Mass Index (BMI)24.0 kg/m^2
STANDARD_DEVIATION 5.1
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Height68.4 inches
STANDARD_DEVIATION 4.2
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
7 Participants
Region of Enrollment
United States
10 participants
Sex: Female, Male
Female
5 Participants
Sex: Female, Male
Male
5 Participants
Skin tone
Dark Skin Tone
3 Participants
Skin tone
Light Skin Tone
4 Participants
Skin tone
Medium Light Skin tone
2 Participants
Skin tone
Medium Skin Tone
1 Participants
Weight161.0 Lbs
STANDARD_DEVIATION 41.4

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 10
other
Total, other adverse events
0 / 10
serious
Total, serious adverse events
0 / 10

Outcome results

Primary

Evaluate SpO2 Accuracy Per Standards for Pulse Oximetry.

This study was a comparative, single-center, non-randomized study conducted to evaluate the SpO2 accuracy per standards and guidelines identified above for SpO2 accuracy for pulse oximetry equipment over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison. As a secondary goal, the pulse rate accuracy was compared to ECG Heart Rate realized over the range throughout the hypoxia procedure. Testing was conducted under normal office environment conditions.

Time frame: 90 Seconds

Population: Five (5) males, five (5) females (age: 19-38yrs, weight: 105-228 lbs, height: 63-75, BMI: 18.0-34.7). Race ethnicity, two (2) Black / African-Americans, one (1) Asian, seven (7) White. Nine (9) Non-Hispanic / Non-Latino, one (1) of Hispanic /Latino. Skin pigmentation ranged from light to dark meeting the requirement of at least 2 darkly pigmented

ArmMeasureValue (MEAN)Dispersion
ARMS SpO2 70-100%Evaluate SpO2 Accuracy Per Standards for Pulse Oximetry.3.1 percentStandard Deviation 0.6
Secondary

The Pulse Rate Accuracy Compared to ECG Heart Rate.

The pulse rate accuracy was compared to ECG Heart Rate as recorded by the S5 Multi-parameter monitor. Passing criteria was an ARMS of 3 bpm or better based measurements observed during the pulse oximetry evaluation.

Time frame: 90 Seconds

Population: Five (5) males, five (5) females (age: 19-38yrs, weight: 105-228 lbs, height: 63-75, BMI: 18.0-34.7). Race / ethnicity, two (2) Black / African-Americans, one (1) Asian, seven (7) White. Nine (9) Non-Hispanic / Non-Latino, one (1) Hispanic /Latino. Skin pigmentation / tones met requirement of at least 2 darkly pigmented or 15 % of the subject pool

ArmMeasureValue (MEAN)Dispersion
ARMS SpO2 70-100%The Pulse Rate Accuracy Compared to ECG Heart Rate.2.7 percentStandard Deviation 6

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026